LOGO
LOGO

Aldeyra To Make Second Bid For FDA Approval Of Dry Eye Disease Drug

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024 lt

Dry eye disease is an ocular condition where the eyes do not produce enough tears or make the right type of tears or tear film. It is estimated that there are approximately 39 million dry eye disease patients in the United States.

The stock we are bringing to your attention today is that of Aldeyra Therapeutics Inc. (ALDX), which despite facing an initial setback in obtaining FDA approval for its investigational dry eye disease treatment last year, is set to make another attempt later this year.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - April 27 – May 01, 2026

May 01, 2026 15:54 ET
Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.

Latest Updates on COVID-19